<DOC>
	<DOCNO>NCT01200368</DOCNO>
	<brief_summary>Subjects randomly assign 1 3 group receive follow vaccine : Group 1 : 13-valent pneumococcal conjugate vaccine ( 13vPnC ) diphtheria , tetanus , acellular pertussis vaccine ( DTaP ) , Group 2 : 7-valent pneumococcal conjugate vaccine ( 7vPnC ) DTaP , Group 3 : DTaP alone . Group 3 subject also receive catch-up dos Prevenar ( commercial product Prevenar Japan ) 13vPnC 7vPnC blind , DTaP open-label . The main purpose study determine immune responses 13vPnC comparable immune response 7vPnC immune response 13vPnC give DTaP comparable induced DTaP give alone . In addition , study aim evaluate side effect ( safety profile ) vaccination 13vPnC 7vPnC give DTaP healthy Japanese infant .</brief_summary>
	<brief_title>Trial Evaluating 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria , Tetanus , Acellular Pertussis Vaccine ( DTaP ) Healthy Japanese Infants</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Male female subject 3 6 month age enrollment . Available entire study period whose parent/legal guardian reach telephone . Healthy infant determine medical history , physical examination , judgement investigator . Previous vaccination license investigational pneumococcal , diphtheria , tetanus , pertussis vaccine . A previous anaphylactic reaction vaccine vaccinerelated component . Bleeding diathesis condition associate prolonged bleeding time would contraindicate type injection . History cultureproven invasive disease cause S pneumoniae ( eg , meningitis , bacteremia , osteomyelitis , arthritis ) . Infant direct descendant ( child , grandchild ) study site personnel .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>6 Months</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>vaccine</keyword>
	<keyword>pneumococcal conjugate</keyword>
</DOC>